The purpose of this study is to evaluate: * What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
rwTTR (real-world time to response)
Timeframe: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
rwORR (real-world overall response rate)
Timeframe: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)
rwDOR (real-world duration of response）
Timeframe: From first response until 18 months
rwPFS (real-world progression-free survival)
Timeframe: From initiation of elranatamab treatment (index date) until 18 months
rwOS (real world overall survival)
Timeframe: From initiation of elranatamab treatment (index date) until 18 months
rwTTNT (real world time to next treatment)
Timeframe: From initiation of elranatamab treatment (index date) until 18 months
Pfizer CT.gov Call Center